We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In this episode of ETF Spotlight, I speak with Tim Seymour, founder & CIO of Seymour Asset Management and co-host of CNBC's Fast Money, about cannabis investing and the Amplify Seymour Cannabis ETF (CNBS - Free Report) , which is the best performing marijuana ETF over the past year.
Cannabis stocks & ETFs are soaring this year, thanks mainly to favorable policy outlook and improving industry fundamentals. Last week, pot stocks saw a lot of interest from traders on Reddit’s WallStreetBets forum.
Investors are now hoping for a more rapid path to full federal legalization with the Democratic majority in both chambers of Congress. Fifteen states and the District of Columbia allow marijuana’s recreational use now and more states are expected to legalize the drug in the aftermath of the pandemic.
We have also seen a pickup in deal making in the space. Jazz Pharmaceuticals (JAZZ - Free Report) is buying GW Pharma for about $7 Billion, while Aphria and Tilray (TLRY - Free Report) are merging to create the biggest global cannabis company.
CNBS has gained more than 180% over the past year, significantly outperforming other marijuana ETFs like AdvisorShares Pure Cannabis ETF (YOLO - Free Report) , The Cannabis ETF , Cambria Cannabis ETF (TOKE - Free Report) , Global X Cannabis ETF , and ETFMG Alternative Harvest ETF (MJ - Free Report) , which have gained between 50% and 150%.
Top holdings in CNBS include GW Pharma, Canopy Growth (CGC - Free Report) and Village Farms (VFF - Free Report) . Tune into the podcast to learn more.
Make sure to be on the lookout for the next edition of ETF Spotlight and also make sure to subscribe! If you have any comments or questions, please email podcast@zacks.com.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Should You Invest in Marijuana Stocks & ETFs Now?
In this episode of ETF Spotlight, I speak with Tim Seymour, founder & CIO of Seymour Asset Management and co-host of CNBC's Fast Money, about cannabis investing and the Amplify Seymour Cannabis ETF (CNBS - Free Report) , which is the best performing marijuana ETF over the past year.
Cannabis stocks & ETFs are soaring this year, thanks mainly to favorable policy outlook and improving industry fundamentals. Last week, pot stocks saw a lot of interest from traders on Reddit’s WallStreetBets forum.
Investors are now hoping for a more rapid path to full federal legalization with the Democratic majority in both chambers of Congress. Fifteen states and the District of Columbia allow marijuana’s recreational use now and more states are expected to legalize the drug in the aftermath of the pandemic.
We have also seen a pickup in deal making in the space. Jazz Pharmaceuticals (JAZZ - Free Report) is buying GW Pharma for about $7 Billion, while Aphria and Tilray (TLRY - Free Report) are merging to create the biggest global cannabis company.
CNBS has gained more than 180% over the past year, significantly outperforming other marijuana ETFs like AdvisorShares Pure Cannabis ETF (YOLO - Free Report) , The Cannabis ETF , Cambria Cannabis ETF (TOKE - Free Report) , Global X Cannabis ETF , and ETFMG Alternative Harvest ETF (MJ - Free Report) , which have gained between 50% and 150%.
Top holdings in CNBS include GW Pharma, Canopy Growth (CGC - Free Report) and Village Farms (VFF - Free Report) . Tune into the podcast to learn more.
Make sure to be on the lookout for the next edition of ETF Spotlight and also make sure to subscribe! If you have any comments or questions, please email podcast@zacks.com.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>